Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market to Reach Over US$ 3.9 Billion By 2025; Upsurge in the Consumption of Antibiotics Across the Globe to Fuel Market Growth, Observes Transparency Market Research


News provided by

Transparency Market Research

15 Mar, 2018, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

ALBANY, New York, March 15, 2018 /PRNewswire/ --

The global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market was valued at approximately US$ 2.9 Bn in 2016 is projected to register cumulative annual growth rate (CAGR) of over 3.2% from 2017 to 2025, according to a new report published by Transparency Market Research titled "Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017-2025". The report suggests that rising incidence of the development of antibiotic resistant strains among all age groups are likely to spur the demand of MRSA Drugs in the coming years (2017 to 2025). As key players introduce novel anti-MRSA agents in developed markets such a North America and Europe, these regions are likely to account for dominating share of the global MRSA Drugs market. Established presence & wide distribution networks of major players and growing market penetration of emerging players are likely to boost growth of Asia Pacific MRSA Drugs market at a CAGR of around 3.7% from 2017 to 2025.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1315

Development of Treatment-Emergent Resistance in MRSA-Infected Patients to Restrain the Growth of MRSA Drugs 

According to CDC, around 33% of the people carry staphylococcus aureus, also known as staph, in their nose. But over the decades, few strains of staph such as MRSA (Methicillin-resistant Staphylococcus Aureus) have become resistant to some antibiotics that once destroyed it. MRSA strains are thus a type of staph that are resistant to beta-lactam antibiotic called methicillin. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. However, increased practice of prescribing antibiotics, 50% of which are unnecessary and inappropriate, is responsible to give rise to treatment-emergent resistance in MRSA-infected patients. According to the CDC, resistance to tigecycline and vancomycin, which are the effective and potent therapeutic options for severe MRSA infection, has emerged. Such treatment-emergent resistant strains developing in the MRSA-infected patients are expected to restrain the growth of MRSA drugs market during the forecast period.

Request a Custom Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1315

Lipopeptide drug class to lose the market share 

The report offers detailed segmentation of global MRSA drugs market on the basis of drug class, route of administration, and distribution channel. Among the drug class, lipopeptide is poised to account for leading share of the global market during the forecast period from 2017 to 2025. However, the segment is expected to lose its market share from 31.6% in 2016 to 30.5% by the end of 2025, owing to the loss of patent exclusivity for daptomycin in 2016, and emergence of generic drug molecules in lipopeptide drug class. Key pharmaceuticals companies such as Pfizer, Inc. involved in the manufacturing of oxazolidinones against MRSA infection, and their strong positioning in the global MRSA drugs market is likely to get boost the growth of oxazolidinone segment during the forecast period.

Oral to Be the Most Promising Route of Administration to Invest In 

Various route of administration offered in the report are oral and parenteral. Parenteral route of administration accounted for highest market share of 72.2% in 2016, due to the increased investment in the pharmaceutical sector by key antibiotics manufacturers to boost the production of intravenous anti-MRSA antibiotics. Oral route of administration is expected to get a boost in terms of revenue by 2025, which is attributable to the key companies involved in the R&D of anti-MRSA vaccines.

Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1315

Online Pharmacy to witness significant growth rate by 2025 

Rise in number of players in the antibiotic manufacturing industry, along with their widespread distribution channels are estimated to propel the market share of the retail pharmacy segment by 2025. Hospital pharmacy is expected to account for a market share of 51.0% by 2025, owing to the increased number of multispecialty hospitals across the globe, and their improved reimbursement policies. However, online pharmacy is likely to register highest CAGR of 3.4% during 2017-2025, due to rise in e-commerce sales, and improvement in digital sales channels to cater to the rising demand-supply gap for antibiotics.

Asia Pacific to Register Exponential Growth Rate and Offer Huge Incremental Opportunity 

Geographically, the global MRSA drugs market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2016, North America accounted for the highest market share in terms of revenue, which is attributable to the investments by U.S. based key players in the R&D of screening tools for MRSA infection. Europe is the second most prominent region in the global MRSA drugs market, which is projected to grow during the forecast period, due to research grants by the public & private players in the European countries to propel the R&D of anti-MRSA antibiotics. However, huge patient pool in the countries of China and India, and uncontrolled consumption of antibiotics in India are estimated to fuel the growth of MRSA drugs market in Asia Pacific with relatively significant CAGR of 3.7% during 2017-2025.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1315

Key Players such as Merck & Co., Inc., and Pfizer, Inc. are Likely to Continue to Lead the Global MRSA Drugs Market 

The prominent players operating in the global MRSA Drugs Market are Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc. Investing in the R&D and clinical trials of unique drug molecules in topical dosage form is the major strategy being adopted by key manufacturers to stay ahead in the rising competition.

Popular Research Reports by TMR: 

  • Drugs of Abuse Testing Market:
    https://www.transparencymarketresearch.com/drugs-abuse-testing-market.html
  • Fragment-based Drug Discovery Market:
    https://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

About Us 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Research Blog: https://theglobalhealthnews.com/

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.